Psychotropics, A to Z
Author: Gordon F S Johnson
Published online: 10 April 2005

He has skilfully condensed essential information on individual psychotropic drugs and presented it in an attractive, user-friendly format. Information on each drug is broken down into five colour-coded sections: therapeutics; side effects; dosage and use; special populations; and the art of psychopharmacology, including how to get the best use out of a drug.
The author also uses a list of icons to alert the reader to the class of drug, mechanism of action and concerns with drug interactions or major side effects.
The drugs are listed in alphabetical order by their generic name and are supplemented by an index with generic and trade names allowing quick and easy reference for the busy clinician.
For the Australian reader, approved indications for each of the drugs may differ from those in the United States so you may need to access the yellow book (Schedule of Pharmaceutical Benefits) to obtain information on PBS listings. Also, some medications are available in the US but are not approved for marketing in Australia. For example, since the book was published, regulatory decisions have led to the withdrawal of nefazodone from the market due to safety issues.
There is considerable duplication of information for drugs of a similar class, such as the selective serotonin reuptake inhibitors (SSRIs). However, the advantage is that the prescriber can readily obtain all the information required on a particular drug without needing to access other chapters of the book.
While the author clearly states in his introduction that certain drugs and combinations of drugs may be for the expert only, this is not always highlighted in the text, such as combination antidepressants with mirtazapine, venlafaxine or SSRIs, colloquially known as Californian rocket fuel.
There is much in this book to recommend it to general practitioners, medical students and experts, but it is a glossy production and at $120 for the paperback, the cost is on the high side.
Gordon F S JohnsonProfessor of Psychological Medicine University of Sydney, NSW
Reorienting Allied Health Into Community-Based Care for People Experiencing Trauma and Social Disadvantage
Simon Rosenbaum, Grace McKeon, Gulsah Kurt, Oscar Lederman, Kemi Wright, Sabuj Kanti Mistry, Jackie E. Curtis, Philip B. Ward, Zachary Steel, Hamish Fibbins, Rachel Morell, Melissa C. Eaton, Andrew Watkins, Ben Harris-Roxas, Brendan Goodger, Eleanor Beck, Megan Teychenne, Joseph Firth, Davy Vancampfort, David Burns, Russell Roberts, Tristan Favaloro, Danielle Weber, Rosanna Barbero, Vasili Maroulis, Melissa Holmes, Stefan Mackenzie, Chiara Mastrogiovanni, Afsana Anwar, Uzma Choudhry, Catherine Sherrington, Jane Currie, Thomas Gadsden, Scott Teasdale
Stigmatising Attitudes Towards People With Depression, Bipolar Disorder, Borderline Personality, ADHD and Early and Long-Term/Untreated Schizophrenia: Representative Survey of Australian Adults
Amy J. Morgan, Anna M. Ross, Gayle McNaught, Rachel Green, Nicola J. Reavley
Psychosocial Hazards for Healthcare Workers: Supporting the Second Victim Also Helps the Primary Victims
Sarah Michael
Supporting Population Mental Health in the Wake of Mass Tragedies
Susan J. Rees, Derrick M. Silove
In the Wake of the National Suicide Prevention Strategy 2025–2035: Suicide Prevention in Type 1 Diabetes
Rigel Paciente, Keely Bebbington, Alix Woolard, Helen Milroy
The risk of death after hospitalisation following intentional self‐poisoning: a retrospective observational study (PAVLOVA‐2)
Firouzeh Noghrehchi, Nicholas A Buckley, Rose Cairns